ProteoTech's intellectual property estate covering new proprietary technologies currently consists of over 225 total patents in its portfolio, including 165 issued patents in the US and Internationally. This extensive portfolio covers technologies relating to:

• Alzheimer's disease
• Parkinson's disease
• Other amyloid diseases such as AL, TTR and AA Amyloidosis, and Type 2 Diabetes

This extensive landscape of intellectual property covers a wide range of applications including:

• Therapeutics (compositions of matter, new chemical entities, synthetic routes and methods of use)
• Diagnostics for Alzheimer's and Parkinson's disease
• Platform in vitro and animal model screening technologies for the development of new compounds